17
May

08:00 AM EDT

Oncology

Strategy Meeting East Coast USA 2022

The premier meeting for all East Coast USA Oncology professionals

Le Meridien Cambridge

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Oncology Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered.

Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Oncology professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Become an official strategy meeting partner

Whatever your business needs, we can help. Get in touch for partnering opportunities

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say...

See the full agenda and facilitator line-up

Download the strategy meeting brochure for full details

DOWNLOAD THE BROCHURE

Meet Our 2022 Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our Oncology strategy meeting.

Susan Weidner

Senior Vice President IntrinsiQ Analytics

Susan Weidner joined IntrinsiQ Specialty Solutions in 2013.  As the Senior Vice President, Susan is responsible for the Analytics business unit along with our community-based research network, AdvanceIQ Network, and our precision medicine strategies.  In her position, she also coordinates activities across both our software and analytics businesses in support of our specialty distribution and physician group purchasing organizations.
With over 20 years of healthcare experience, she has led the design, development and implementation of innovative healthcare solutions, including those driven by healthcare informatics.  Leveraging her expertise in clinical and outcomes research along with health economics, she has assisted pharmaceutical companies, payers and provider organizations in demonstrating the value of their product(s) and/or organizations.
Prior to joining IntrinsiQ Specialty Solutions, Susan held executive leadership positions at pharmaceutical, healthcare consulting, and precision medicine companies.

Sarrah Val

MPH Vice President of Global Sales MD GROUP

Claudia Hesselmann, PhD

Co-founder & CEO ARENSIA

Tatiana Eidus

Director, Corporate Development North America Arensia

Ashley Herrick

Executive Director, Oncology Program Strategy Premier Research

Amit Agarwal

SVP, Clinical Development Arch Oncology

Amit Agarwal MD PhD is the Senior VP of Clinical Development at Arch Oncology. Arch is a privately-held, clinical stage immune-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer. Prior to joining Arch, Dr. Agarwal was the global disease lead for Multiple Myeloma at Bristol Myers Squibb. He was responsible for guiding the multiple myeloma portfolio development strategy including CAR T, CelMods and other assets. Previously he also served as the US Medical Affairs lead at Celgene and lead several approvals and launches. Dr. Agarwal is a board-certified hematologist and oncologist with extensive clinical development experience in phase 1-4 studies. Early in his career he was faculty at the University of Arizona where he provided care for patients with hematological malignancies and served as the principal investigator for several clinical trials and lead translational research.  Dr. Agarwal completed his internal medicine and oncology training at the University of Arizona. He holds a PhD from Virginia Commonwealth University and M.B.B.S. from University of Pune.

Darren Dasburg

Biotech Executive Contango Ventures Inc

Session – International shipping logistics strategies and addressing regulations associated
Bringing over 39 years of technical operations experience in a variety of small and large molecule settings, Darren Dasburg recently departed AstraZeneca as Vice President Global PMO & Strategy in 2017 after his role as Site GM for the Boulder Manufacturing Center beginning in September 2015 when AstraZeneca/MedImmune acquired the former Amgen biologics production facility, retrofitted and started up through 2017. He is currently in advancing discussions for cell and gene therapy start-ups. 
Previously, Darren held the position of Vice President MedI BioVentures building partnerships in Korea, Japan and China for biosimilar development. Before then, VP of Capacity Utilization with where he led the first of its kind capacity sharing arrangement to support bio-manufacturing production. Prior to that, he was a Founding Partner in a consulting venture where he provided executive management team leadership in the areas of technical operations, manufacturing operations, project management, and business strategy. Darren did his formative years and ultimately served as Vice President of Corporate Engineering with GlaxoSmithKline. 
Darren holds a Bachelor’s of Science in Mechanical Engineering from Colorado State University and a MBA from Duke University’s Fuqua School of Business and advanced certificates in biotechnology from MIT. He is a licensed Professional Engineer in North Carolina and has worked on the ISPE Bio Mfg Conference since it’s inception.

Agnieszka Denslow

Associate Director Pharmacology/ Toxicology Oncorus

Sashka Dimitrievska

Global Therapeutic Area Head Oncology Clinical Insights AstraZeneca

Wendy Hauck

Global Associate Medical Director (Oncology) Eisai Inc

Sarah Hersey

Vice President, Precision Medicine Bristol Myers Squibb

Jeffrey Humphrey

Member of Board of Directors Constellation Pharmaceuticals

Dr. Jeff Humphrey is currently Chief Medical Officer of Constellation Pharmaceuticals overseeing development of a pipeline of drugs that modify epigenetic regulation of gene expression. Previously at Kyowa Kirin as Chief Development Officer, he built US and EU research capabilities and guided development of burosumab, mogamulizumab, and istradefylline to approvals and US/EU launches (Poteligeo®, Nourianz®, Crysvita®). Dr. Humphrey began industry clinical research at Bristol-Myers Squibb and subsequently served in management positions for early and late drug development and medical affairs at Pfizer, Bayer, and Bristol Myers Squibb, participating in development of novel oncology drugs in all phases, from pre-IND to post-launch (Nexavar®, Erbitux®, Sprycel®, Yervoy®). Dr. Humphrey is a graduate of Harvard College and CWRU School of Medicine, and completed medical residency at the Johns Hopkins Hospital and post-doctoral fellowships in human genetics and medical oncology at the US National Institutes of Health and National Cancer Institute, where he was board-certified in oncology.

Vijay Kasturi

Vice President, Clinical Development/ Medical Affairs AVEO Oncology

An accomplished hematologist-oncologist and researcher, Dr. Vijay Kasturi oversees the medical affairs team at Aveo Oncology. For more than 25 years Vijay has built a stellar career establishing and executing global and regional strategies that have brought innovative new treatment options to patients in hematology and oncology.
Prior to joining Aveo, Vijay was SVP of Scientific Affairs at FerGene, and led both Medical Affairs and Clinical Development.  He has also led U.S. Medical Affairs, Oncology for EMD Serono where he had broad leadership responsibilities, including external stakeholder  management, evidence generation, medical education and publication strategy. During his time with EMD Serono, Vijay also developed and managed the global medical strategy and launch plan for the company’s anti-PD-L1 agent (avelumab), including indications in Merkel cell, urothelial, and kidney cancer.
Earlier in this career, Vijay served as an Assistant Professor of Medicine, Division of Hematology-Oncology  at the University of Massachusetts Medical School and was the program leader for genitourinary oncology at UMass Memorial Cancer Center. He trained in Hematology-Oncology at the National Cancer Institute  and worked as an investigator and physician at the National Cancer Institute and at Dartmouth Hitchcock  Medical Center.
He has authored numerous publications and has been the recipient of numerous awards for his work in   medicine.

Randi Isaacs

Chief Medical Officer Werewolf Therapeutics

Dr. Randi Isaacs is a veteran hematologist and oncologist focused on discovery and development of novel therapeutic approaches in oncology, specializing in immunotherapy, biologic agents, and cell therapies for the treatment of solid tumors and hematologic malignancies. She has devoted her career to bringing new therapeutics to cancer patients to improve clinical outcomes and has made contributions to several successfully registered drugs.
 
Dr. Isaacs has more than 20 years’ experience in clinical and translational oncology drug development, most recently as the Executive Director and Clinical Site Head of Translational Clinical Oncology at the Novartis Institutes for Biomedical Research (NIBR). She previously held executive leadership roles in oncology and clinical development at Merck, Schering Plough, and Sandoz, where she led projects in all phases of clinical research and supported business development and licensing.
 
Prior to transitioning to biopharma, Dr. Isaacs held various academic appointments including Assistant Professor of Medicine in the Division of Hematology/Oncology at the State University of New York Health Sciences Center and Clinical Assistant Professor of Hematology/Oncology at the University of Medicine and Dentistry of New Jersey.
 
Dr. Isaacs earned her B.A. in Chemistry from Wellesley College and holds an M.D. from Dartmouth Medical School. She completed her residency and postdoctoral training at the University of California San Francisco and the Memorial Sloan-Kettering Cancer Center, respectively.

Anson Pierce

Associate Director, Clinical Biomarker Innovation and Developmen Takeda

Jessicca Rege

VP, Head of Oncology Alkermes

Khalid Shah

Vice Chair of Research, Director Center for Stem Cell Therapeutics and Imaging , Associate Professor Harvard Medial School

Session – Cell based therapies for Cancer: Journey from Innovation to Translation
Dr. Khalid Shah is the Vice Chair of Research at Brigham and Women’s Hospital (BWH) in Boston, MA. He is also the Director of the Center for Stem Cell Therapeutics and Imaging and a Principal Faculty at Harvard Stem Cell Institute in Boston.
In recent years, Dr. Shah and his team have pioneered major developments in the cancer research field, successfully developing therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, JNCI, Stem Cells, Lancet Oncology and Nature Reviews Cancer. The potential of developing novel cancer therapies in his laboratory has been recognized by many cancer alliances and associations. Based on this, he has received the young investigator award from ACGT, Research fellow award from ACS, Innovation awards from James McDonnell Foundation, ABTA, Goldhirsh Foundation and American Association of Radiology. Recently, Dr. Shah’s work has been highlighted in the media world-wide including features on BBC and CNN. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. The technologies from Dr. Shah’s laboratory have led to the foundation of a biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients.
Dr. Shah has participated in the training of numerous undergraduate, graduate students and residents at MGH and the potential of his mentoring has been recognized by Harvard Medical School, who awarded him the Harvard Young Mentor Award. Dr. Shah has also launched an outreach program to create public awareness of the fervent need for effective cancer treatments, and the current research on the cusp of clinical translation that would yield paramount progress for cancer patients.

Amanda Wang

VP Immuno Oncology Precision Medicine Bayer

Arvin Yang

Chief Medical Officer Mersana Therapeutics

Arvin joined Mersana in November 2020, bringing deep experience in leading early-stage trials and late-stage global registrational trials. Prior to joining Mersana, Arvin spent over a decade at Bristol Myers Squibb in various roles with increasing responsibility for the clinical development of hematology and oncology including immuno-oncology therapies. Most recently, he was Vice President and Head of Clinical Hematology. Before that, he was Vice President and Development Lead for Melanoma and GU cancers, and played a critical role in the global approval of nivolumab and nivolumab plus ipilimumab combinations in a number of indications. Earlier, he was responsible for the nivolumab and ipilimumab life-cycle clinical development plans including those in gynecological cancers. Finally, he has held leadership roles overseeing a pipeline of early clinical programs as well as roles in medical affairs.  
Dr. Yang received his M.D. and Ph.D. from Rutgers Robert Wood Johnson Medical School and completed training in internal medicine at Beth Israel Deaconess, Harvard Medical School and in oncology at Memorial Sloan-Kettering Cancer Center.

Natalie LaFranzo

Director Personalis

Emilie Louvet

Clinical Information Science Director, Information Practice, Oncology Biometrics Astrazeneca

First name	Last name	Job title	Company name	Photo URL	Bio Position
Susan	Weidner	Senior Vice President	IntrinsiQ Analytics	https://proventainternational.com/wp-content/uploads/2021/09/Susan-Weidner.jpg	Susan Weidner joined IntrinsiQ Specialty Solutions in 2013. As the Senior Vice President, Susan is responsible for the Analytics business unit along with our community-based research network, AdvanceIQ Network, and our precision medicine strategies. In her position, she also coordinates activities across both our software and analytics businesses in support of our specialty distribution and physician group purchasing organizations. With over 20 years of healthcare experience, she has led the design, development and implementation of innovative healthcare solutions, including those driven by healthcare informatics. Leveraging her expertise in clinical and outcomes research along with health economics, she has assisted pharmaceutical companies, payers and provider organizations in demonstrating the value of their product(s) and/or organizations. Prior to joining IntrinsiQ Specialty Solutions, Susan held executive leadership positions at pharmaceutical, healthcare consulting, and precision medicine companies.
Sarrah	Val	MPH Vice President of Global Sales	MD GROUP	https://proventainternational.com/wp-content/uploads/2022/02/Sarrah-Val.jpg	Earned her Masters in Public Health from the University of Southern California after completing a dual degree in Integrative Physiology and Mathematics from the University of Colorado, Boulder. She is driven by her love for patient care, and invests her industry efforts into making clinical trials more accessible, equitable, and patient-focused. With prior experience in Medical Affairs and as a Director of Clinical Operations, she has led clinical trials from protocol design through FDA approval, driven physician education initiatives, and facilitated post-market and investigator grant research.
Claudia	Hesselmann, PhD	Co-founder & CEO	ARENSIA	https://proventainternational.com/wp-content/uploads/2020/01/Claudia-Hesselmann-Arensia-Headshot-e1584469734743.png	Claudia Hesselmann, PhD, a chemist by training, with a PhD in molecular biology. Claudia has twenty years of expertise in the early phases of drug development. Her experience includes co-founding and holding management positions in various CROs. Her extensive background and social acumen, along with her first-hand knowledge of the industry, led Claudia to co-found ARENSIA Exploratory Medicine in Düsseldorf, Germany. Her primary aim is the contribution of innovative approaches to bring about substantial acceleration to the drug development process and enable more agile patient access to novel therapeutics.
Tatiana	Eidus	Director, Corporate Development North America	Arensia	https://proventainternational.com/wp-content/uploads/2020/05/Tatiana-Eidus.jpg	Tatiana Eidus received her Master’s Degree in Biophysics from Moscow State University. Entering the industry more than a decade ago, Tatiana has accumulated wide expertise in all the operational aspects of initiating and managing Phase I-III trials across Europe and US. Prior to joining ARENSIA Exploratory Medicine, Tatiana worked for GSK and Merck. Primarily focused on early-stage exploratory programs, she conducted trials in various disease areas. In her current role as Director Corporate Development, Tatiana supports ARENSIA’s partners in the US, supervising cross-functional coordination throughout study planning, start-up and execution.
Ashley	Herrick	Executive Director, Oncology Program Strategy	Premier Research	https://proventainternational.com/wp-content/uploads/2021/09/Ashley-Herrick-e1631526374503.jpg	Dr. Ashley Herrick provides strategic planning, coordination, knowledge, and expertise for Premier Research’s oncology sponsors. She has more than 13 years of experience in oncology clinical trial oversight and drug development. Dr. Herrick holds a doctorate degree in molecular and cellular biology with a focus on hematologic malignancies from Baylor College of Medicine. She is CCRP-certified and is a member of the American Association for Cancer Research and the American Society of Clinical Oncology. She’s also an active volunteer with the Leukemia and Lymphoma Society.
Amit	Agarwal	SVP, Clinical Development	Arch Oncology	https://proventainternational.com/wp-content/uploads/2021/09/Amit-Agarwal-scaled-e1631527361280.jpg	Amit Agarwal MD PhD is the Senior VP of Clinical Development at Arch Oncology. Arch is a privately-held, clinical stage immune-oncology company that aims to discover and develop potential best-in-class antibody therapies for the treatment of patients with cancer. Prior to joining Arch, Dr. Agarwal was the global disease lead for Multiple Myeloma at Bristol Myers Squibb. He was responsible for guiding the multiple myeloma portfolio development strategy including CAR T, CelMods and other assets. Previously he also served as the US Medical Affairs lead at Celgene and lead several approvals and launches. Dr. Agarwal is a board-certified hematologist and oncologist with extensive clinical development experience in phase 1-4 studies. Early in his career he was faculty at the University of Arizona where he provided care for patients with hematological malignancies and served as the principal investigator for several clinical trials and lead translational research. Dr. Agarwal completed his internal medicine and oncology training at the University of Arizona. He holds a PhD from Virginia Commonwealth University and M.B.B.S. from University of Pune.
Darren	Dasburg	Biotech Executive	Contango Ventures Inc	https://proventainternational.com/wp-content/uploads/2020/01/Darren-Dasburg.jpg	Session – International shipping logistics strategies and addressing regulations associated Bringing over 39 years of technical operations experience in a variety of small and large molecule settings, Darren Dasburg recently departed AstraZeneca as Vice President Global PMO & Strategy in 2017 after his role as Site GM for the Boulder Manufacturing Center beginning in September 2015 when AstraZeneca/MedImmune acquired the former Amgen biologics production facility, retrofitted and started up through 2017. He is currently in advancing discussions for cell and gene therapy start-ups. Previously, Darren held the position of Vice President MedI BioVentures building partnerships in Korea, Japan and China for biosimilar development. Before then, VP of Capacity Utilization with where he led the first of its kind capacity sharing arrangement to support bio-manufacturing production. Prior to that, he was a Founding Partner in a consulting venture where he provided executive management team leadership in the areas of technical operations, manufacturing operations, project management, and business strategy. Darren did his formative years and ultimately served as Vice President of Corporate Engineering with GlaxoSmithKline. Darren holds a Bachelor’s of Science in Mechanical Engineering from Colorado State University and a MBA from Duke University’s Fuqua School of Business and advanced certificates in biotechnology from MIT. He is a licensed Professional Engineer in North Carolina and has worked on the ISPE Bio Mfg Conference since it’s inception.
Agnieszka	Denslow	Associate Director Pharmacology/ Toxicology	Oncorus	https://proventainternational.com/wp-content/uploads/2022/04/Agnieszka-Denslow.jpg
Sashka	Dimitrievska	Global Therapeutic Area Head Oncology Clinical Insights	AstraZeneca	https://proventainternational.com/wp-content/uploads/2021/02/Sashka-Dimitrievska.jpeg	Sashka leads the Global AstraZeneca Oncology Information Practice (IP) department focused on generating informed decisions in late stage drug development across the oncology portfolio. Prior to joining AstraZeneca in 2017, Sashka worked in Alexion Pharmaceuticals Strategy & Intelligence, followed by a role in Alexion US Marketing. She holds a PhD in Biomedical Engineering and an MBA training from Yale University.
Wendy	Hauck	Global Associate Medical Director (Oncology)	Eisai Inc	https://proventainternational.com/wp-content/uploads/2021/12/Wendy-Hauck.jpg
Sarah	Hersey	Vice President, Precision Medicine	Bristol Myers Squibb	https://proventainternational.com/wp-content/uploads/2021/09/Sarah-Hersey.jpeg	Sarah Hersey is the Global Head of Future Precision Medicine for Novartis and previously held the position of Global Program Diagnostics, Executive Director at Novartis. Prior to joining Novartis, Sarah held multiple roles within Johnson and Johnson (Janssen Pharmaceuticals, Janssen Diagnostics & Ortho-Clinical Diagnostics) including Global Head of Operations, Assay Program Leader for Companion Diagnostics Center of Excellence, and Director of Materials and Process Development and Enabling Technologies. Sarah has BS and MS degrees in Chemistry and Biology from Northern Illinois University, Regulatory Affairs Certification (RAC), and an MBA from California State University.
Jeffrey	Humphrey	Member of Board of Directors	Constellation Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2021/02/Jeffrey-Humphrey-1.jpg	Dr. Jeff Humphrey is currently Chief Medical Officer of Constellation Pharmaceuticals overseeing development of a pipeline of drugs that modify epigenetic regulation of gene expression. Previously at Kyowa Kirin as Chief Development Officer, he built US and EU research capabilities and guided development of burosumab, mogamulizumab, and istradefylline to approvals and US/EU launches (Poteligeo®, Nourianz®, Crysvita®). Dr. Humphrey began industry clinical research at Bristol-Myers Squibb and subsequently served in management positions for early and late drug development and medical affairs at Pfizer, Bayer, and Bristol Myers Squibb, participating in development of novel oncology drugs in all phases, from pre-IND to post-launch (Nexavar®, Erbitux®, Sprycel®, Yervoy®). Dr. Humphrey is a graduate of Harvard College and CWRU School of Medicine, and completed medical residency at the Johns Hopkins Hospital and post-doctoral fellowships in human genetics and medical oncology at the US National Institutes of Health and National Cancer Institute, where he was board-certified in oncology.
Vijay	Kasturi	Vice President, Clinical Development/ Medical Affairs	AVEO Oncology	https://proventainternational.com/wp-content/uploads/2021/09/Vijay-Kasturi-scaled-e1631527003583.jpg	An accomplished hematologist-oncologist and researcher, Dr. Vijay Kasturi oversees the medical affairs team at Aveo Oncology. For more than 25 years Vijay has built a stellar career establishing and executing global and regional strategies that have brought innovative new treatment options to patients in hematology and oncology. Prior to joining Aveo, Vijay was SVP of Scientific Affairs at FerGene, and led both Medical Affairs and Clinical Development. He has also led U.S. Medical Affairs, Oncology for EMD Serono where he had broad leadership responsibilities, including external stakeholder management, evidence generation, medical education and publication strategy. During his time with EMD Serono, Vijay also developed and managed the global medical strategy and launch plan for the company’s anti-PD-L1 agent (avelumab), including indications in Merkel cell, urothelial, and kidney cancer. Earlier in this career, Vijay served as an Assistant Professor of Medicine, Division of Hematology-Oncology at the University of Massachusetts Medical School and was the program leader for genitourinary oncology at UMass Memorial Cancer Center. He trained in Hematology-Oncology at the National Cancer Institute and worked as an investigator and physician at the National Cancer Institute and at Dartmouth Hitchcock Medical Center. He has authored numerous publications and has been the recipient of numerous awards for his work in medicine.
Randi	Isaacs	Chief Medical Officer	Werewolf Therapeutics	https://proventainternational.com/wp-content/uploads/2021/12/Raandi.jpg	Dr. Randi Isaacs is a veteran hematologist and oncologist focused on discovery and development of novel therapeutic approaches in oncology, specializing in immunotherapy, biologic agents, and cell therapies for the treatment of solid tumors and hematologic malignancies. She has devoted her career to bringing new therapeutics to cancer patients to improve clinical outcomes and has made contributions to several successfully registered drugs. Dr. Isaacs has more than 20 years’ experience in clinical and translational oncology drug development, most recently as the Executive Director and Clinical Site Head of Translational Clinical Oncology at the Novartis Institutes for Biomedical Research (NIBR). She previously held executive leadership roles in oncology and clinical development at Merck, Schering Plough, and Sandoz, where she led projects in all phases of clinical research and supported business development and licensing. Prior to transitioning to biopharma, Dr. Isaacs held various academic appointments including Assistant Professor of Medicine in the Division of Hematology/Oncology at the State University of New York Health Sciences Center and Clinical Assistant Professor of Hematology/Oncology at the University of Medicine and Dentistry of New Jersey. Dr. Isaacs earned her B.A. in Chemistry from Wellesley College and holds an M.D. from Dartmouth Medical School. She completed her residency and postdoctoral training at the University of California San Francisco and the Memorial Sloan-Kettering Cancer Center, respectively.
Anson	Pierce	Associate Director, Clinical Biomarker Innovation and Developmen	Takeda	https://proventainternational.com/wp-content/uploads/2022/03/user-icon-1.png
Jessicca	Rege	VP, Head of Oncology	Alkermes	https://proventainternational.com/wp-content/uploads/2021/02/jessicca-rege-1.jpeg	Jessicca is an experienced oncology leader with over 15 years of experience in the pharmaceutical industry. She currently is the vice president head of oncology research at Alkermes, responsible for clinical oversight and development of the oncology portfolio. Prior to that she was the chief development officer of a oncology biotech Oncologie (OnXcerna) responsible for oversite of all aspects of R&D including research, CMC, operations, regulatory, and translational medicine. She also served as Global Chief of Staff for the Cancer Enterprise in Daiichi-Sankyo where she took a central role in supporting the Global Head of Oncology R&D in both strategic planning and implementation of their global portfolio. Prior to this, she held various leadership roles in both large and small pharmaceutical companies in both clinical development and medical affairs supporting the development and approval of various oncology products.
Khalid	Shah	Vice Chair of Research, Director Center for Stem Cell Therapeutics and Imaging , Associate Professor	Harvard Medial School	https://proventainternational.com/wp-content/uploads/2020/03/Khalif-Shah.jpg	Session – Cell based therapies for Cancer: Journey from Innovation to Translation Dr. Khalid Shah is the Vice Chair of Research at Brigham and Women’s Hospital (BWH) in Boston, MA. He is also the Director of the Center for Stem Cell Therapeutics and Imaging and a Principal Faculty at Harvard Stem Cell Institute in Boston. In recent years, Dr. Shah and his team have pioneered major developments in the cancer research field, successfully developing therapeutic stem cells for cancer, particularly brain tumors. These studies have been published in a number of very high impact journals like Nature Neuroscience, PNAS, JNCI, Stem Cells, Lancet Oncology and Nature Reviews Cancer. The potential of developing novel cancer therapies in his laboratory has been recognized by many cancer alliances and associations. Based on this, he has received the young investigator award from ACGT, Research fellow award from ACS, Innovation awards from James McDonnell Foundation, ABTA, Goldhirsh Foundation and American Association of Radiology. Recently, Dr. Shah’s work has been highlighted in the media world-wide including features on BBC and CNN. Dr. Shah holds current positions on numerous councils, advisory and editorial boards in the fields of stem cell therapy and oncology. The technologies from Dr. Shah’s laboratory have led to the foundation of a biotech company, AMASA Technologies Inc. whose main objective is the clinical translation of therapeutic stem cells in cancer patients. Dr. Shah has participated in the training of numerous undergraduate, graduate students and residents at MGH and the potential of his mentoring has been recognized by Harvard Medical School, who awarded him the Harvard Young Mentor Award. Dr. Shah has also launched an outreach program to create public awareness of the fervent need for effective cancer treatments, and the current research on the cusp of clinical translation that would yield paramount progress for cancer patients.
Amanda	Wang	VP Immuno Oncology Precision Medicine	Bayer	https://proventainternational.com/wp-content/uploads/2022/03/Amanda-Wang.jpg	Amanda studied Biochemistry and Molecular Biology in University of Virginia and did her PhD in electron microscopic studies of helical protein polymers. Besides, she studied Biostatistics in the master program at Boston University and did research in genome wide associate analyses. Amanda started her career at Novartis as Biomarker Expert in the Translation Medicine Biomarker Development Group, where she supported clinical development across several therapeutic areas including autoimmunity and inflammatory diseases. Later Amanda moved to the Novartis Oncology drug development team where she led biomarker analyses and interpretations across the IO portfolio. After 9.5 years with Novartis, Amanda joined Bayer Oncology Precision Medicine group as Director Precision Medicine Lead in IO. In 2021 Amanda was promoted to VP overseeing the IO/CART franchise of Bayer Oncology Precision Medicine.
Arvin	Yang	Chief Medical Officer	Mersana Therapeutics	https://proventainternational.com/wp-content/uploads/2021/09/Arvin-Yang-e1631527204670.jpg	Arvin joined Mersana in November 2020, bringing deep experience in leading early-stage trials and late-stage global registrational trials. Prior to joining Mersana, Arvin spent over a decade at Bristol Myers Squibb in various roles with increasing responsibility for the clinical development of hematology and oncology including immuno-oncology therapies. Most recently, he was Vice President and Head of Clinical Hematology. Before that, he was Vice President and Development Lead for Melanoma and GU cancers, and played a critical role in the global approval of nivolumab and nivolumab plus ipilimumab combinations in a number of indications. Earlier, he was responsible for the nivolumab and ipilimumab life-cycle clinical development plans including those in gynecological cancers. Finally, he has held leadership roles overseeing a pipeline of early clinical programs as well as roles in medical affairs. Dr. Yang received his M.D. and Ph.D. from Rutgers Robert Wood Johnson Medical School and completed training in internal medicine at Beth Israel Deaconess, Harvard Medical School and in oncology at Memorial Sloan-Kettering Cancer Center.
Natalie	LaFranzo	Director	Personalis	https://proventainternational.com/wp-content/uploads/2022/04/Natalie-LaFranzo.jpg	Natalie LaFranzo is a Director at Personalis, a next generation genomics company dedicated to delivering tumor-informed comprehensive insights to enable patient-centered diagnostics. Since receiving her PhD in Chemistry at Washington University in St. Louis in 2013, she has held numerous commercial roles in biotech. Previously, she helped launch Predictive Immune Modeling, a multidimensional approach to RNA biomarkers, which enabled the development of Cofactor Genomics’ OncoPrism RNA diagnostic. As a part of Horizon Discovery’s Diagnostics Division, she also launched and supported diagnostic reference standards.
Emilie	Louvet	Clinical Information Science Director, Information Practice, Oncology Biometrics	Astrazeneca	https://proventainternational.com/wp-content/uploads/2022/05/Emilie-Louvet.jpg	Emilie Louvet PhD is currently a Clinical Information Science Director in Oncology Information Practice at AstraZeneca. She is leading Early Oncology initiatives and Digital Solutions to enable portfolio investment decisions. Emilie gained her PhD from Paris 5 University and Institut Jacques Monod (France). She continued and led her research at the Karolinska Institute (Sweden) and at Kyoto University (Japan). She then came back to Europe to co-lead a digital pathology group at Gustave Roussy (France). Prior to joining Information Practice, Emilie has held several roles in AstraZeneca in Translational and Precision Medicine, as well as supporting the Data strategy and Value for Oncology. Emilie, not only in AstraZeneca, but also prior to moving to the industry, has been dedicating her career to Oncology and Cancer Biology.

Susan Weidner, Sarrah Val, Claudia Hesselmann, PhD, Tatiana Eidus, Ashley Herrick, Amit Agarwal, Darren Dasburg, Agnieszka Denslow, Sashka Dimitrievska, Wendy Hauck, Sarah Hersey, Jeffrey Humphrey, Vijay Kasturi, Randi Isaacs, Anson Pierce, Jessicca Rege, Khalid Shah, Amanda Wang, Arvin Yang, Natalie LaFranzo, Emilie Louvet

Here To Help

Want to know more? Interested in sponsoring the event? Need help registering your team? Just get in touch and a member of the team will be happy to help.

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Medicinal Chemistry Strategy Meeting East Coast – Boston 2024

Oncology

Strategy Meeting East Coast USA 2022

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Meridien Cambridge

Fresh Oncology Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Become an official strategy meeting partner

Press play to hear what your colleagues had to say...

See the full agenda and facilitator line-up

Meet Our 2022 Facilitators

Susan Weidner

Sarrah Val

Claudia Hesselmann, PhD

Tatiana Eidus

Ashley Herrick

Amit Agarwal

Darren Dasburg

Agnieszka Denslow

Sashka Dimitrievska

Wendy Hauck

Sarah Hersey

Jeffrey Humphrey

Vijay Kasturi

Randi Isaacs

Anson Pierce

Jessicca Rege

Khalid Shah

Amanda Wang

Arvin Yang

Natalie LaFranzo

Emilie Louvet

Our 2022 Thought Leader

Our 2022 Co-Hosts

Here To Help

Want to find out more?

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Psychiatry

Dermatology

Internal diseases

Respiratory

Diabetes

Metabolic diseases

Rheumatology

Endocrinology

Nephrology

Surgery

ENT

Neurology

Urology

Gastroenterology

Le Meridien Cambridge